Efficacy News and Research

RSS
Elusys awarded second contract to develop Anthim for treatment of anthrax infection

Elusys awarded second contract to develop Anthim for treatment of anthrax infection

TapImmune inks smallpox vaccine Research and Technology License Option Agreement with Mayo Clinic

TapImmune inks smallpox vaccine Research and Technology License Option Agreement with Mayo Clinic

Lux Biosciences receives CRL for Voclosporin

Lux Biosciences receives CRL for Voclosporin

NanoBio Corporation receives U.S. patent for nanoemulsion technology

NanoBio Corporation receives U.S. patent for nanoemulsion technology

FDA issues Lux Biosciences Complete Response letter for Luveniq NDA

FDA issues Lux Biosciences Complete Response letter for Luveniq NDA

Scientists discover Deep Brain Stimulation as potential treatment for early Alzheimer's

Scientists discover Deep Brain Stimulation as potential treatment for early Alzheimer's

Discovery Laboratories reports net loss of $6.3 million for second-quarter 2010

Discovery Laboratories reports net loss of $6.3 million for second-quarter 2010

Study supports efficacy of brief intervention in reducing alcohol use, violence among adolescents

Study supports efficacy of brief intervention in reducing alcohol use, violence among adolescents

NCI panel recommends Celsion's Phase III ThermoDox HEAT Study as Priority Clinical Trial for HCC

NCI panel recommends Celsion's Phase III ThermoDox HEAT Study as Priority Clinical Trial for HCC

Matrixx Initiatives first-quarter net loss reduces to $2.4 million

Matrixx Initiatives first-quarter net loss reduces to $2.4 million

Special issue on new developments in vestibular rehabilitation

Special issue on new developments in vestibular rehabilitation

ZymoGenetics second-quarter net loss declines to $3.8 million

ZymoGenetics second-quarter net loss declines to $3.8 million

Excaliard reports positive results from EXC 001 Phase 2 clinical trial for reducing scar severity

Excaliard reports positive results from EXC 001 Phase 2 clinical trial for reducing scar severity

MAP Pharmaceuticals reports net loss of $12.5M for second-quarter 2010

MAP Pharmaceuticals reports net loss of $12.5M for second-quarter 2010

Curis reports net loss of $2.1 million for second-quarter 2010

Curis reports net loss of $2.1 million for second-quarter 2010

Titan completes 60% enrollment in confirmatory Phase 3 clinical study of Probuphine for opioid addiction

Titan completes 60% enrollment in confirmatory Phase 3 clinical study of Probuphine for opioid addiction

ArQule, Daiichi Sankyo announce decision to advance ARQ 197 into Phase 3 clinical trial for NSCLC

ArQule, Daiichi Sankyo announce decision to advance ARQ 197 into Phase 3 clinical trial for NSCLC

Oxygen Biotherapeutics collaborates with U.S. Navy to develop treatment for DCS

Oxygen Biotherapeutics collaborates with U.S. Navy to develop treatment for DCS

VIVUS second-quarter total revenue decreases to $3.9 million

VIVUS second-quarter total revenue decreases to $3.9 million

BioMarin provides update on PEG-PAL Phase 2 clinical study for phenylketonuria

BioMarin provides update on PEG-PAL Phase 2 clinical study for phenylketonuria

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.